CEACAM5 and cancer: These beneficial radioimmunotherapy results are in line with the initial phase I clinical trials using 90Y-labeled chimeric antibody T84.66 [24,62] and the recent phase I clinical trial using the same radionuclide for labeling a humanized version of the antibody (90Y-DOTA-M5A) for advanced CEA producing cancers [14].